Crescita Therapeutics, Inc. (CTX) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

With a growth in Net Sales of 52.47%, the company declared Very Positive results in Jun 25

OPERATING CASH FLOW(Y) Highest at CAD 1.29 MM
RAW MATERIAL COST(Y) Fallen by -18.3% (YoY)
DEBTORS TURNOVER RATIO(HY) Highest at 8.87%

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

CAD 8 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.48

Return on Equity

6.13%

Price to Book

0.52

Revenue and Profits:

Net Sales:

6 Million

(Quarterly Results - Jun 2025)

Net Profit:

1 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-6.67%

6 Months

-16.0%

1 Year

-22.22%

2 Years

5.0%

3 Years

-36.36%

4 Years

-38.24%

5 Years

-48.78%

Crescita Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Crescita Therapeutics Reports Significant Sales Growth Amid Valuation Adjustments and Operational Efficiency Improvements

Crescita Therapeutics, Inc. has recently experienced a change in its evaluation, reflecting a shift in valuation metrics. The company reported a 52.47% increase in net sales for the quarter ending June 2025 and improved operational efficiency, despite being categorized as risky compared to historical valuations.

Crescita Therapeutics Adjusts Valuation Amid Strong Sales Growth and Market Challenges

Crescita Therapeutics, Inc. has recently experienced a change in its evaluation, highlighting its financial metrics and market position. The company reported a 52.47% increase in net sales for the quarter ending June 2025 and achieved its highest operating cash flow, indicating effective cash management amidst a complex financial landscape.

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

5.77%

EBIT Growth (5y)

-188.25%

EBIT to Interest (avg)

-0.90

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.54

Sales to Capital Employed (avg)

1.08

Tax Ratio

0.46%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.23%

ROE (avg)

2.50%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.56

EV to EBIT

-0.55

EV to EBITDA

-1.06

EV to Capital Employed

0.13

EV to Sales

0.05

PEG Ratio

Dividend Yield

ROCE (Latest)

-24.27%

ROE (Latest)

-9.11%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Bearish

Dow Theory

No Trend

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 51.22% vs -21.15% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 188.89% vs -200.00% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "6.20",
          "val2": "4.10",
          "chgp": "51.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "0.90",
          "val2": "-0.70",
          "chgp": "228.57%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "0.80",
          "val2": "-0.90",
          "chgp": "188.89%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "93.50%",
          "val2": "-255.40%",
          "chgp": "34.89%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 12.00% vs -25.53% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -40.00% vs -322.22% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "19.60",
          "val2": "17.50",
          "chgp": "12.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.80",
          "val2": "-0.50",
          "chgp": "-260.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.80",
          "val2": "-2.00",
          "chgp": "-40.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-164.20%",
          "val2": "-111.60%",
          "chgp": "-5.26%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Jun'25

Jun'24

Change(%)

Net Sales

6.20

4.10

51.22%

Operating Profit (PBDIT) excl Other Income

0.90

-0.70

228.57%

Interest

0.00

Exceptional Items

-0.00

0.00

Consolidate Net Profit

0.80

-0.90

188.89%

Operating Profit Margin (Excl OI)

93.50%

-255.40%

34.89%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Jun 2025 is 51.22% vs -21.15% in Jun 2024

Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 188.89% vs -200.00% in Jun 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

19.60

17.50

12.00%

Operating Profit (PBDIT) excl Other Income

-1.80

-0.50

-260.00%

Interest

0.10

Exceptional Items

0.10

-0.00

Consolidate Net Profit

-2.80

-2.00

-40.00%

Operating Profit Margin (Excl OI)

-164.20%

-111.60%

-5.26%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 12.00% vs -25.53% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -40.00% vs -322.22% in Dec 2023

All Annual Results

Company CV

About Crescita Therapeutics, Inc.

Crescita Therapeutics, Inc.

Pharmaceuticals & Biotechnology

Crescita Therapeutics Inc. is a drug development company. The Company owns products for treating medical conditions in dermatology and pain. It owns various drug delivery platforms, which include Durapeel and Foam technology to support the development of patented formulations that can deliver actives into or through the skin. It operates two business units: the Topical Products and Technology (TPT) Group and the Immunology Group. The TPT Group product, Pliaglis and other products are focused on dermatology and pain. Its product Flexicaine is in Phase II clinical stage and has therapeutic area in Tick-borne disease. Its product Ibuprofen Foam is in pre-clinical stage and has therapeutic area in Acute Pain. Its product Terbinafine is in pre-clinical stage and has therapeutic area in Onychomycosis. Its product Mical 1 is in pre-clinical stage and has therapeutic area in Psoriasis. Its product Mical 2 is in pre-clinical stage and has therapeutic area in Dermatological skin treatment.

Company Coordinates

Company Details

6733 Mississauga Rd Suite 610 , MISSISSAUGA ON : L5N 6J5

Tel: 1 450 6804722

http://www.crescitatherapeutics.com/

Registrar Details

Crescita Therapeutics, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

MarketsMojo — Loved in India, Now Global

Dashboard

With a growth in Net Sales of 52.47%, the company declared Very Positive results in Jun 25

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Crescita Therapeutics Reports Significant Sales Growth Amid Valuation Adjustments and Operational Efficiency Improvements

Crescita Therapeutics Adjusts Valuation Amid Strong Sales Growth and Market Challenges

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Crescita Therapeutics, Inc.

Company Coordinates